PL2928477T3 - Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy - Google Patents

Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy

Info

Publication number
PL2928477T3
PL2928477T3 PL13861008T PL13861008T PL2928477T3 PL 2928477 T3 PL2928477 T3 PL 2928477T3 PL 13861008 T PL13861008 T PL 13861008T PL 13861008 T PL13861008 T PL 13861008T PL 2928477 T3 PL2928477 T3 PL 2928477T3
Authority
PL
Poland
Prior art keywords
myelofibrosis
treatment
telomerase inhibitor
imetelstat
inhibitor imetelstat
Prior art date
Application number
PL13861008T
Other languages
English (en)
Inventor
Monic J. Stuart
Stephen Kelsey
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of PL2928477T3 publication Critical patent/PL2928477T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL13861008T 2012-12-07 2013-11-15 Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy PL2928477T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05
EP13861008.4A EP2928477B1 (en) 2012-12-07 2013-11-15 Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis
PCT/US2013/070437 WO2014088785A1 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
PL2928477T3 true PL2928477T3 (pl) 2020-03-31

Family

ID=50883867

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13861008T PL2928477T3 (pl) 2012-12-07 2013-11-15 Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy
PL18196690T PL3456333T3 (pl) 2012-12-07 2013-11-15 Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18196690T PL3456333T3 (pl) 2012-12-07 2013-11-15 Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego

Country Status (34)

Country Link
EP (3) EP3456333B8 (pl)
JP (5) JP6433911B2 (pl)
KR (3) KR102662590B1 (pl)
CN (2) CN104936602B (pl)
AP (1) AP2015008504A0 (pl)
AU (3) AU2013356533B2 (pl)
BR (1) BR112015013260A2 (pl)
CA (2) CA2892907C (pl)
CL (2) CL2015001530A1 (pl)
CY (2) CY1122169T1 (pl)
DK (3) DK3646876T3 (pl)
EA (1) EA032973B1 (pl)
ES (2) ES2789176T3 (pl)
FI (1) FI3646876T3 (pl)
HK (2) HK1210940A1 (pl)
HR (2) HRP20191784T1 (pl)
HU (2) HUE045098T2 (pl)
IL (2) IL239266B (pl)
LT (3) LT3456333T (pl)
MA (2) MA45504B1 (pl)
ME (1) ME03538B (pl)
MX (3) MX2015007169A (pl)
MY (1) MY180634A (pl)
NZ (1) NZ708920A (pl)
PH (1) PH12015501282A1 (pl)
PL (2) PL2928477T3 (pl)
PT (2) PT3456333T (pl)
RS (2) RS60401B1 (pl)
SG (3) SG10201802926XA (pl)
SI (2) SI3456333T1 (pl)
TN (1) TN2015000249A1 (pl)
UA (2) UA117116C2 (pl)
WO (1) WO2014088785A1 (pl)
ZA (2) ZA201504124B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1778711T (pt) 2004-07-02 2017-10-19 Geron Corp Síntese de monómeros nucleosídeos 3'-amino protegidos
ES2717777T3 (es) * 2013-11-06 2019-06-25 Mayo Found Medical Education & Res Métodos y materiales para tratar neoplasias hematológicas
SI3286203T1 (sl) * 2015-04-23 2020-10-30 Geron Corporation Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TW201919705A (zh) * 2017-07-28 2019-06-01 美商健生生物科技公司 治療骨髓增生不良症候群之方法
AU2019263064A1 (en) * 2018-04-30 2020-12-03 Kartos Therapeutics, Inc. Methods of treating cancer
WO2021091904A1 (en) * 2019-11-04 2021-05-14 Geron Corporation Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP2007525414A (ja) * 2003-01-31 2007-09-06 ジェシー エル エス オウ スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
EP3682903A1 (en) 2003-09-09 2020-07-22 Geron Corporation Modified oligonucleotides for telomerase inhibition
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
PT1778711T (pt) 2004-07-02 2017-10-19 Geron Corp Síntese de monómeros nucleosídeos 3'-amino protegidos
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
HUE041448T2 (hu) 2006-10-30 2019-05-28 Geron Corp Kombinált telomerázgátló és gemcitabin rák kezelésére
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP3456333B1 (en) 2020-04-01
JP2022179684A (ja) 2022-12-02
CN104936602B (zh) 2020-07-17
CY1123206T1 (el) 2021-10-29
IL239266B (en) 2019-11-28
RS59363B1 (sr) 2019-11-29
JP2020041001A (ja) 2020-03-19
CY1122169T1 (el) 2020-11-25
SG10202103341SA (en) 2021-05-28
MA38193B1 (fr) 2018-12-31
AU2013356533A1 (en) 2014-06-12
TN2015000249A1 (en) 2016-10-03
LT3646876T (lt) 2024-05-10
RS60401B1 (sr) 2020-07-31
LT2928477T (lt) 2019-10-10
EP3456333A1 (en) 2019-03-20
CA3188494A1 (en) 2014-06-12
EP3646876B1 (en) 2024-02-14
IL239266A0 (en) 2015-07-30
NZ748134A (en) 2020-10-30
MA38193A1 (fr) 2017-12-29
CN111617252A (zh) 2020-09-04
WO2014088785A8 (en) 2015-07-16
UA126015C2 (uk) 2022-08-03
HRP20191784T1 (hr) 2019-12-27
PL3456333T3 (pl) 2020-09-21
SG10201802926XA (en) 2018-05-30
PH12015501282B1 (en) 2015-08-24
KR102662590B1 (ko) 2024-05-03
JP2016504307A (ja) 2016-02-12
PT2928477T (pt) 2019-10-25
ZA202108991B (en) 2023-05-31
HK1210940A1 (en) 2016-05-13
FI3646876T3 (fi) 2024-05-14
SI2928477T1 (sl) 2019-11-29
KR20150091130A (ko) 2015-08-07
JP2022050537A (ja) 2022-03-30
JP7288098B2 (ja) 2023-06-06
EP2928477A4 (en) 2016-09-21
AU2020267142B2 (en) 2024-05-16
DK3456333T3 (da) 2020-05-18
WO2014088785A1 (en) 2014-06-12
CN104936602A (zh) 2015-09-23
MA45504B1 (fr) 2021-10-29
MA45504A1 (fr) 2020-05-29
MX2020003276A (es) 2020-07-20
EP3456333B8 (en) 2020-05-13
EP2928477B1 (en) 2019-07-24
NZ708920A (en) 2020-08-28
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
ZA201504124B (en) 2017-05-31
JP6433911B2 (ja) 2018-12-05
MX2022015437A (es) 2023-01-11
ES2744790T3 (es) 2020-02-26
IL280144A (en) 2021-03-01
DK2928477T3 (da) 2019-10-07
PT3456333T (pt) 2020-06-01
HUE049858T2 (hu) 2020-11-30
CA2892907C (en) 2023-03-21
AU2020267142A1 (en) 2020-12-03
HK1212226A1 (en) 2016-06-10
EP2928477A1 (en) 2015-10-14
DK3646876T3 (da) 2024-05-06
EP3646876A1 (en) 2020-05-06
UA117116C2 (uk) 2018-06-25
EA201590878A1 (ru) 2016-04-29
SG11201504383TA (en) 2015-07-30
JP2018035196A (ja) 2018-03-08
ME03538B (me) 2020-07-20
LT3456333T (lt) 2020-06-25
CL2015001530A1 (es) 2016-03-28
KR20210107906A (ko) 2021-09-01
BR112015013260A2 (pt) 2018-02-06
JP6998191B2 (ja) 2022-02-04
CA2892907A1 (en) 2014-06-12
PH12015501282A1 (en) 2015-08-24
KR20230028590A (ko) 2023-02-28
MX2015007169A (es) 2016-03-31
AU2018282364A1 (en) 2019-05-23
CL2017002156A1 (es) 2018-05-04
SI3456333T1 (sl) 2020-10-30
KR102294819B1 (ko) 2021-09-01
AU2013356533B2 (en) 2018-09-27
AP2015008504A0 (en) 2015-06-30
MY180634A (en) 2020-12-03
ES2789176T3 (es) 2020-10-26
EA032973B1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HK1210174A1 (en) Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases
HK1207583A1 (en) Use of biotin for the treatment of multiple sclerosis
SG11201501173SA (en) PI3Kδ INHIBITOR
EP2826473A4 (en) NEW USE OF PATCHOULOL
ZA201406082B (en) Use of ccr3-inhibitors
PL2928477T3 (pl) Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
EP2968204A4 (en) TREATMENT WITH A PHOSPHODIESTERASE HEMMER
HK1203054A1 (en) Dinuceloside polyphosphates for the treatment of pain
EP2882880A4 (en) TREATMENT OF MANGANEAN MATERIALS
EP2895504A4 (en) TRPV3 AGONISTS FOR THE TREATMENT OF SKIN DISEASES
SG11201403246PA (en) Treatment of manganese-containing materials
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
HK1200094A1 (en) Use of immunomodulators for the treatment of cancer
GB201318433D0 (en) Candidate for the treatment of epilepsy